Fate Therapeutics បញ្ចប់កិច្ចសហប្រតិបត្តិការជាមួយ Janssen កាត់បន្ថយបុគ្គលិក

• Fate Therapeutics Inc (ផ្សារហ៊ុន NASDAQ: FATE) មាន decided to terminate the collaboration and option agreement with Janssen Biotech Incដែលជា Johnson & Johnson unit (NYSE: JNJ), on revised terms and conditions.

• The agreement has been terminated, and all collaboration activities will be wound down in the first quarter of 2023.

• “We are disappointed that we were not able to align with Janssen on their proposal for continuation of our collaboration,” Fate CEO Scott Wolchko said.

• The company is reducing its headcount to approximately 220 employees. It will discontinue some of its natural killer cell programs in acute myeloid leukemia, B-cell lymphoma, and solid tumors.

• Fate Therapeutics ended the fourth quarter with approximately $475 million in cash, cash equivalents, and receivables. Based on its pipeline prioritization and expense reduction, the company expects a cash runway by 2025.

• The pact was initially signed in 2020, and Fate Therapeutics received $100 million in cash and stock and almost $3 billion in milestone payments.

• សកម្មភាពតម្លៃ: FATE shares are down 62.80% at $4.10 on the last check Friday.

មើលអ្វីផ្សេងបន្ថែមទៀតរបស់ Benzinga

កុំខកខានការជូនដំណឹងតាមពេលវេលាជាក់ស្តែងលើភាគហ៊ុនរបស់អ្នក – ចូលរួម ប្រូម៉ាណា ដោយ​ឥតគិតថ្លៃ! សាកល្បងឧបករណ៍ដែលនឹងជួយអ្នកឱ្យវិនិយោគកាន់តែឆ្លាតវៃ លឿនជាងមុន និងប្រសើរជាងមុន។.

© ២០២០ Benzinga.com ។ Benzinga មិនផ្តល់ដំបូន្មានវិនិយោគទេ។ រក្សា​រ​សិទ្ធ​គ្រប់យ៉ាង។